Medibank Private Share Offer – Read a free article with opinions that may differ from The Motley Fool’s premium investment services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources and more. Learn more
At the time of writing, Medibank shares are at $3,165, down 0.47%. In comparison, the S&P/ASX 200 (ASX: XJO ) struggled throughout the day to trade at 6,977.9, down 1.23%.
Medibank Private Share Offer
Almost halfway through the year, Australia’s largest health insurance provider, Medibank, has released its key dates for 2022.
Medibank Private Ipo
The most important date in the near future is August 18, when the company will present its full-year results.
The ex-dividend date is scheduled for next month, September 7. This is when investors should have bought Medibank shares to receive the upcoming dividend.
In context, Medibank returned to shareholders a final dividend payment of 6.9 cents for FY21.
Finally, the company will hold its 2022 Annual General Meeting (AGM) on November 16. This is likely to summarize the events of the last 12 months as well as the short-term outlook for the private health insurer.
Company News Tag Results
Since this time last year, Medibank’s share price has capped and is up around 5%.
Healthcare shares down 20% since mid-August, this ASX 300 stock now ‘undervalued’: expert 7 Oct 2022 | Monica O’Shea has had a good run this week, but could this ASX 300 share be headed higher? Read more » Healthcare Shares CSL’s share price had a strong first quarter. What’s next for you? October 7, 2022 | The Zach Bristow biotech company continues to be on the sidelines in the longer term. Read more » Profit sharing boom! Guess which ASX All Ords share is up 50% this week 6 October 2022 | Monica O’Shea We look at why this ASX Ords share has soared. Read more » Healthcare PolyNovo’s share price rises 13% in record quarter October 6, 2022 | Shares of James Mickleboro PolyNovo rose sharply on Thursday. That’s why… read more » Healthcare Shares 2 ASX Healthcare shares you haven’t heard of: Expert 5 Oct 2022 | Tony Yeo If you’re looking to invest in a sector that people still need in the economic downturn, here are a couple of small… Read More » Health Care Stocks Start Looking More Attractive In October? October 4, 2022 | Brooke Cooper Another expert added her voice to the bull chorus. Read more » Healthcare stocks Why did Paradigm’s stock price rise 19% today? October 4, 2022 | Shares of this James Mickleborough drug company are on fire today… Read More » Healthcare Stocks Why Mesoblast’s Share Price Jumped 8% On Monday? October 3, 2022 | Monica O’Shea takes a look at the latest Mesoblast update. Read more “
In this free stock report, Scott Phillips and his team at Motley’s Share Advisor have published a special free report detailing 5 ASX stocks that they believe could be fantastic stocks to own as investors prepare for retirement. 2 Important notices The offer The offer is contained in this prospectus. is an invitation to purchase fully paid ordinary shares in Medibank Private Limited (ABN) (MPL) (the Shares). The offer in Australia and New Zealand is made through this prospectus. Filing and Listing This prospectus is dated 20 October 2014 and filed with the Australian Securities and Investments Commission (ASIC) on that date. Neither ASIC, ASX Limited (ASX) nor their respective officers accept responsibility for the contents of this prospectus or the substance of the investment to which this prospectus relates. MPL will apply to ASX for listing and quotation of its shares on the ASX within seven days of the date of this prospectus (the prospectus date). At the time of the Offer, the Commonwealth of Australia and MPL may provide information to investors in Australia of any significant new developments relating to the Offer by means of advertisements in Australian newspapers. ASIC has permitted the publication of any supplementary prospectus that may require an advertisement placed in at least two daily newspapers of general circulation throughout Australia and in one daily newspaper of general circulation in each state and territory of Australia. A copy of each supplemental prospectus will also be delivered on the offering expiration date. This prospectus will expire 13 months after the date of the prospectus (the expiration date) and no shares will be issued or transferred pursuant to this prospectus after the expiration date. NOTE TO APPLICANTS The information contained in this prospectus is not financial product advice and does not address the investment objectives, financial situation or specific needs of any potential investor. It is important that you read this prospectus carefully and in its entirety before deciding to invest in MPL. In particular, when considering MPL’s prospects, you should consider the risks that may affect the financial performance of MPL and its controlled entities (collectively known as Medibank Private). You should carefully consider these risks in light of your personal circumstances, investment objectives, financial situation and specific needs (including financial and tax matters) and seek professional advice from your accountant, financial advisor, stockbroker, lawyer or other professional advisor before deciding. Invest in MPL. Some of the key risks that prospective investors should consider are set out in Sections 1 and 5. There may be risks other than those listed in these sections that should be considered based on your individual circumstances. No person named in this prospectus or any other person guarantees the performance of Medibank Private, the repayment of the capital or the payment of the remuneration on the shares. As set out in Section 7, the Shares are expected to be listed on the ASX initially on a contingent and deferred settlement basis. Commonwealth and MPL disclaim all liability, whether in negligence or otherwise, to persons who trade in Shares prior to receipt of the Transaction Confirmation Statement. No offer where the offer would be illegal. This prospectus does not constitute an offer or solicitation anywhere or to any person to whom it would not be lawful to make such an offer or solicitation. No action has been taken to register or qualify the Shares or the Offer or otherwise to permit a public offer of the Shares in any jurisdiction outside Australia and New Zealand. Distribution of this prospectus (including in electronic form) outside Australia and New Zealand may be restricted by law and persons acquiring this prospectus outside Australia and New Zealand should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. This prospectus may not be distributed or relied upon by any person in the United States unless accompanied by an institutional offering memorandum as part of the institutional offering. The shares have not been and will not be registered under the US Securities Act of 1933 (the US Securities Act) or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, under the in the United States, unless the shares are registered under US securities law, or are offered or sold pursuant to an exemption from the US Securities Act and applicable US securities laws or in a transaction not subject to registration requirements. See the section for more information on selling restrictions that apply to the offer and sale of shares outside Australia. Information for New Zealanders New Zealand Reciprocity No offers to New Zealand investors under this prospectus will be made until the exposure period (defined below) has expired. The Offer to New Zealand Investors is a regulated offer made under the laws of Australia and New Zealand. In Australia this is Chapter 8 of the Corporations Act 2001 (Cth) (the Corporations Act) and the Corporations Regulations 2001 (Cth) (the Corporations Rules). In New Zealand this is section 5 of the Securities Act 1978 (NZ) and the Securities (Mutual Recognition of Offers of Securities in Australia) Regulations 2008 (NZ). The Offer and the contents of this prospectus are governed primarily by the laws of Australia and not New Zealand. Generally, the Corporations Act and the Corporations Regulations set out how the offer must be made. There are differences in how securities are regulated under Australian law. For example, the disclosure of fees for collective investment schemes is different under the Australian regime. The rights, remedies and indemnification arrangements available to New Zealand investors in Australian securities may differ from the rights, remedies and indemnification arrangements in New Zealand securities. Both the Australian and New Zealand securities regulators have enforcement obligations in relation to the offering. If you need to make a complaint about the offer, please contact the Financial Markets Authority, Wellington, New Zealand
